Cargando…

The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia

INTRODUCTION: Motivation deficit is a significant aspect of lack of improvement in patients with schizophrenia especially with predominant negative symptoms (PNS). Therefore, improvement depends not only on symptoms reduction and better social functioning but also on patient engagement which is a ke...

Descripción completa

Detalles Bibliográficos
Autores principales: Laszlovszky, I., Dombi, Z.B., Balogh, Á., Barabássy, Á., Vass, G., Szatmári, B., Németh, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475933/
http://dx.doi.org/10.1192/j.eurpsy.2021.1423
_version_ 1784790025583460352
author Laszlovszky, I.
Dombi, Z.B.
Balogh, Á.
Barabássy, Á.
Vass, G.
Szatmári, B.
Németh, G.
author_facet Laszlovszky, I.
Dombi, Z.B.
Balogh, Á.
Barabássy, Á.
Vass, G.
Szatmári, B.
Németh, G.
author_sort Laszlovszky, I.
collection PubMed
description INTRODUCTION: Motivation deficit is a significant aspect of lack of improvement in patients with schizophrenia especially with predominant negative symptoms (PNS). Therefore, improvement depends not only on symptoms reduction and better social functioning but also on patient engagement which is a key but less investigated aspect of successful treatment. OBJECTIVES: To investigate and compare patient engagement in PNS patients after cariprazine and risperidone treatment characterized by the 11 items of the Positive and Negative Syndrome Scale (PANSS-11). METHODS: In this phase 3 study patients suffering from PNS of schizophrenia (PANSS-FSNS≥24) were randomized to 26 weeks of treatment with either cariprazine or risperidone (target dose 4.5 and 4 mg/day, respectively). To compare the effects of the two drugs on patient engagement the PANSS-11 scale was used. Change from baseline (CfB) on the selected items and PANSS-11 total score were analyzed using mixed model of repeated measures approach without correction for multiplicity. RESULTS: PANSS-11 total score mean CfB were -11.20 (SD=0.43) for cariprazine-, and -9.44 (SD=0.45) for risperidone-treated patients with a -1.79 (95% CI=-3.01, -0.56) mean difference (p=0.004) in favor of cariprazine. Most item differences were statistically significant (N1, N2, N3, N4, N5, G16) or numerically higher (N6, G7, G13) for cariprazine versus risperidone. CONCLUSIONS: Cariprazine significantly improved patient engagement in patients with PNS of schizophrenia compared to risperidone based on the PANSS-11 post-hoc analysis. These results suggest that cariprazine treatment may improve not only the symptoms and everyday functioning of PNS patients but their engagement with life. CONFLICT OF INTEREST: Studies were funded by Gedeon Richter Plc. and Allergan Plc (prior to its acquisition by AbbVie). Dr. Laszlovszky, Dombi, Balogh, Dr Barabassy, Dr Vass, Dr. Szatmári and Dr. Németh are employees of Gedeon Richter Plc.
format Online
Article
Text
id pubmed-9475933
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-94759332022-09-29 The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia Laszlovszky, I. Dombi, Z.B. Balogh, Á. Barabássy, Á. Vass, G. Szatmári, B. Németh, G. Eur Psychiatry Abstract INTRODUCTION: Motivation deficit is a significant aspect of lack of improvement in patients with schizophrenia especially with predominant negative symptoms (PNS). Therefore, improvement depends not only on symptoms reduction and better social functioning but also on patient engagement which is a key but less investigated aspect of successful treatment. OBJECTIVES: To investigate and compare patient engagement in PNS patients after cariprazine and risperidone treatment characterized by the 11 items of the Positive and Negative Syndrome Scale (PANSS-11). METHODS: In this phase 3 study patients suffering from PNS of schizophrenia (PANSS-FSNS≥24) were randomized to 26 weeks of treatment with either cariprazine or risperidone (target dose 4.5 and 4 mg/day, respectively). To compare the effects of the two drugs on patient engagement the PANSS-11 scale was used. Change from baseline (CfB) on the selected items and PANSS-11 total score were analyzed using mixed model of repeated measures approach without correction for multiplicity. RESULTS: PANSS-11 total score mean CfB were -11.20 (SD=0.43) for cariprazine-, and -9.44 (SD=0.45) for risperidone-treated patients with a -1.79 (95% CI=-3.01, -0.56) mean difference (p=0.004) in favor of cariprazine. Most item differences were statistically significant (N1, N2, N3, N4, N5, G16) or numerically higher (N6, G7, G13) for cariprazine versus risperidone. CONCLUSIONS: Cariprazine significantly improved patient engagement in patients with PNS of schizophrenia compared to risperidone based on the PANSS-11 post-hoc analysis. These results suggest that cariprazine treatment may improve not only the symptoms and everyday functioning of PNS patients but their engagement with life. CONFLICT OF INTEREST: Studies were funded by Gedeon Richter Plc. and Allergan Plc (prior to its acquisition by AbbVie). Dr. Laszlovszky, Dombi, Balogh, Dr Barabassy, Dr Vass, Dr. Szatmári and Dr. Németh are employees of Gedeon Richter Plc. Cambridge University Press 2021-08-13 /pmc/articles/PMC9475933/ http://dx.doi.org/10.1192/j.eurpsy.2021.1423 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Laszlovszky, I.
Dombi, Z.B.
Balogh, Á.
Barabássy, Á.
Vass, G.
Szatmári, B.
Németh, G.
The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia
title The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia
title_full The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia
title_fullStr The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia
title_full_unstemmed The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia
title_short The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia
title_sort effect of cariprazine on patient engagement: post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475933/
http://dx.doi.org/10.1192/j.eurpsy.2021.1423
work_keys_str_mv AT laszlovszkyi theeffectofcariprazineonpatientengagementposthocanalysisofaphase3studyinpatientswithpredominantnegativesymptomsofschizophrenia
AT dombizb theeffectofcariprazineonpatientengagementposthocanalysisofaphase3studyinpatientswithpredominantnegativesymptomsofschizophrenia
AT balogha theeffectofcariprazineonpatientengagementposthocanalysisofaphase3studyinpatientswithpredominantnegativesymptomsofschizophrenia
AT barabassya theeffectofcariprazineonpatientengagementposthocanalysisofaphase3studyinpatientswithpredominantnegativesymptomsofschizophrenia
AT vassg theeffectofcariprazineonpatientengagementposthocanalysisofaphase3studyinpatientswithpredominantnegativesymptomsofschizophrenia
AT szatmarib theeffectofcariprazineonpatientengagementposthocanalysisofaphase3studyinpatientswithpredominantnegativesymptomsofschizophrenia
AT nemethg theeffectofcariprazineonpatientengagementposthocanalysisofaphase3studyinpatientswithpredominantnegativesymptomsofschizophrenia
AT laszlovszkyi effectofcariprazineonpatientengagementposthocanalysisofaphase3studyinpatientswithpredominantnegativesymptomsofschizophrenia
AT dombizb effectofcariprazineonpatientengagementposthocanalysisofaphase3studyinpatientswithpredominantnegativesymptomsofschizophrenia
AT balogha effectofcariprazineonpatientengagementposthocanalysisofaphase3studyinpatientswithpredominantnegativesymptomsofschizophrenia
AT barabassya effectofcariprazineonpatientengagementposthocanalysisofaphase3studyinpatientswithpredominantnegativesymptomsofschizophrenia
AT vassg effectofcariprazineonpatientengagementposthocanalysisofaphase3studyinpatientswithpredominantnegativesymptomsofschizophrenia
AT szatmarib effectofcariprazineonpatientengagementposthocanalysisofaphase3studyinpatientswithpredominantnegativesymptomsofschizophrenia
AT nemethg effectofcariprazineonpatientengagementposthocanalysisofaphase3studyinpatientswithpredominantnegativesymptomsofschizophrenia